Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
Starling Oncology (NASDAQ: STLN) will release its third quarter 2026 financial results on November 5, 2026, followed by a conference call.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Starling Oncology (NASDAQ: STLN) will release its third quarter 2026 financial results on November 5, 2026, followed by a conference call. The call begins at 5:00 p.m. Eastern Time and will also be webcast through the company’s Investor Relations website. A telephone replay will be available approximately three hours after the call until November 19, 2026, at 11:59 p.m. Eastern Time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 financial results on Thursday, November 5, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
The conference call can be accessed live over the phone by dialing 1-800-347-6865 or, for international callers, 1-203-518-9757, and referencing Conference ID: STARLING. A replay will be available approximately three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the replay is 11162885. The replay will be available until 11:59 p.m. (Eastern Time) on Thursday, November 19, 2026.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.
About Starling Oncology, Inc.
Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.
Contacts
Media
ICR Healthcare
StarlingPR@icrhealthcare.com
Investors
ICR Healthcare
StarlingIR@icrhealthcare.com
